Amanote Research
Register
Sign In
PRS31 Economic Evaluation of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) From the Public Payer Perspective in Brazil
Value in Health
- United Kingdom
doi 10.1016/j.jval.2011.08.1418
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2011
Authors
C. Suzuki
N.L. Silva
Publisher
Elsevier BV
Related search
Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Evaluation of the Economic and Social Burden of Chronic Obstructive Pulmonary Disease (COPD)
Biotechnology and Biotechnological Equipment
Biotechnology
Prs42 - Cost-Effectiveness of Indacaterol/Glycopyrronium in the Treatment of Chronic Obstructive Pulmonary Disease in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Economic Burden in Direct Costs of Chronic Obstructive Pulmonary Disease (COPD) in Turkey: A Payor Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Chronic Obstructive Pulmonary Disease (COPD) Treatment in the Elderly
BMC Geriatrics
Gerontology
Geriatrics
Evaluation of Risk Factors Causing Osteoporosis in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Pain in People With Chronic Obstructive Pulmonary Disease (COPD)
Respiratory Medicine
Pulmonary
Respiratory Medicine
Validation of the Airways Questionnaire 20 - AQ20 in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Brazil
Jornal de Pneumologia
Characteristics of Chronic Obstructive Pulmonary Disease in Spain From a Gender Perspective
BMC Pulmonary Medicine
Pulmonary
Respiratory Medicine
